suMMARY Thirty fetuses with cardiac arrythmias were referred for ultrasonography. This included cross sectional and M mode echocardiography and pulsed Doppler analysis of the fetal heart. Three types of arrhythmias were observed: ectopic beats, tachyarrhythmias, and bradycardia. Ectopic beats were associated with cardiac structural abnormalities in two cases, resulting in fetal death in one. Tachycardia was not associated with structural defect, but death from cardiac failure occurred in one patient. Transplacental treatment for tachyarrhythmia was not successful in our experience. In the group with bradycardia four cases had congenital cardiac abnormalities and the mortality rate was 50%.
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When a fetal cardiac arrhythmia has been established careful structural and rhythm analysis is of vital importance in facilitating prognosis, planning of time and mode of delivery, and monitoring of transplacental treatment where indicated.
Increasing attention is being paid to the prenatal diagnosis of cardiac structural defects by means of real time cross sectional scanners'-4 and the value of M mode recordings in the analysis of cardiac arrhythmias. [5] [6] [7] [8] This study emphasises the importance of careful structural and rhythm analysis of the fetal heart when a cardiac arrhythmia has been established.
Patients and methods
Between January 1982 and April 1983 30 patients with fetal cardiac arrhythmias were referred to our ultrasound unit. The gestational age ranged from 21 to 41 weeks (median 31-9 weeks), maternal parity from 1 to 6 (median 2), and maternal age from 20 to 36 years (median 27-4 years). There was no history of congenital heart disease.
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Atrial flutter with variable AV conduction; Caesarean section at 36 weeks; structurally mild PE; structurally normal heart normal heart; control of dysrhythmia with digitalis; alive and well at 1 year 552 a 7 r t f f i * X f * 7 S t * i , 9 S i S , S S S * < j S ' < ' S ' ' ( < # ' ' ' ' S a ' ' * 5 S s f S S S 4 k > u s R v 7 7 > S S f S , S 4 S S # 4 X > > S w S S i > s S . s S j + t S ____ _ S S _ E < S V < S b S / Z S S S * . 7 , S S , , 7 , S ' V S -b 7 , -M S 7 . ' S -j 7 t * 7 . i S . . . . . . _ .  _ & j , , _ , -X _ _ * , , , 7 j _ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . * . . + . _ , , , , . S Y S t ' 4 S 4 _ , , , ' , , , , j t { v A -. . , 4 ' ' 9 V V . . . . , . . . . . r , g , *  § , j , , , atrioventricular block in one case, was uncertain in one case, and probable mild sinus bradycardia in the remaining patient. In four (50%) patients bradycardia was associated with a structural cardiac anomaly. Tachycardia was assessed as paroxysmal supraventricular tachycardia with spontaneous resolution in the 32nd week of pregnancy in one case, atrial flutter with variable atrioventricular conduction in three cases, and atrial flutter with variable atrioventricular conduction and short bursts of normal sinus rhythm in the remaining case. One patient (case 29) had a normal heart rate as shown on the cardiotocogram but was shown to have atrial flutter with variable atrioventricular conduction on M mode echocardiography (Fig. 2) . In three cases maternal administration of 075 mg digitalis daily failed to cardiovert the tachyarrhythmia. tional information on cardiac function since it is well correlated with total cardiac output.'0
In a prospective study of fetal heart rate and rhythm Southall et al. I I found an incidence of 1-2% of premature beats, which was similar to that (O.80/o) in healthy neonates.'2 These ectopic beats were considered benign and to be associated with a good prognosis. In our series, however, two (11.8%) cases with ectopic beats had associated structural abnormalities (Fig. 3) resulting in fetal death in one. These instances emphasise the need for detailed structural analysis of the heart in the presence of arrhythmias. Regular screening of fetuses without structural defect is recommended as triggering of a sustained arrhythmia may occur from one of these ectopic beats. 13 Vaginal delivery should be possible in cases in which isolated ectopic beats are found.
In our study bradycardia was associated with a 50%/o mortality rate. One fetus (case 19) with no structural abnormality and complete congenital heart block associated with maternal Waldenstrom's disease died two days postpartum from intractable cardiac failure. The remaining three fetuses had associated structural heart disease and congestive cardiac failure and died in utero or shortly after birth.
It is clear from these data that fetuses with structural heart disease or evidence of congestive cardiac failure in the presence of sustained arrhythmia, or both, have a more ominous prognosis. Until 554 and ascites may have played some part in the availability of these drugs to the fetus, but a report by Klein et al.19 describing failure of treatment before the development of hydrops may indicate a more complicated mechanism in some cases. The transmission of verapanil across the placenta is variable,20 but verapamil was selected in this case in which the arrhythmia proved refractory to digitalis and procainamide.
Case 29 showed periods of normal sinus rhythm, which were initially attributed to successful treatment with digitalis. We subsequently learnt that the maternal serum digitalis concentrations were 05 ng/ml at the first recording of normal sinus rhythm. Despite the periods of normal sinus rhythm this fetus developed enlargement of the right heart and mild pericardial effusion, resulting in delivery by caesarean section at >38 weeks' gestation. Careful monitoring by all methods is mandatory in all fetuses with tachyarrhythmia as this is a high risk group. Transplacental treatment must be attempted in the hope of achieving cardioversion and preventing congestive cardiac failure in the previable fetus. In the viable fetus refractory arrhythmias should be further treated by elective caesarean section and pharmacological or electrical cardioversion immediately after birth.
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